FOXP3 and type 1 diabetes mellitus: Polymorphisms in multiple genes in the IL‐2 pathway can predispose to T1D,42, 43, 44 and defects in IL‐2 receptor signalling reduce Foxp3 expression in CD25+ regulatory T cells in T1D patients, prompting trials of both low‐dose IL‐2 and Treg cell therapy.45, 46, 47